

SPECIALTY GUIDELINE MANAGEMENT

PRALUENT (alirocumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease, who require additional lowering of low density lipoprotein cholesterol (LDL-C).

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. Clinical atherosclerotic cardiovascular disease (ASCVD)

Authorization of 12 months may be granted for members who meet ALL of the criteria listed below:

1. Member has a history of clinical ASCVD (See Appendix A).
2. Member meets at least ONE of the following requirements [a or b]:
 - a. Member has a current LDL-C level ≥ 70 mg/dL after at least three months of treatment with a high-intensity statin dose (e.g., atorvastatin ≥ 40 mg or rosuvastatin ≥ 20 mg daily) plus ezetimibe 10 mg daily. If the member is unable to tolerate a high-intensity statin dose, a moderate-intensity statin dose (e.g., atorvastatin 20 mg or equivalent) may be used.
 - b. Member has a current LDL-C level ≥ 70 mg/dL with contraindication or intolerance to statins (See Appendix B and C).

B. Heterozygous Familial Hypercholesterolemia (HeFH)

Authorization of 12 months may be granted for members who meet ALL of the criteria listed below:

1. Member has a diagnosis of familial hypercholesterolemia (See Appendix D).
2. Member meets at least ONE of the following requirements [a, b, c or d]:
 - a. With ASCVD: See Section A.
 - b. Without ASCVD: Member has a current LDL-C level ≥ 100 mg/dL after at least three months of treatment with a high-intensity statin dose (i.e., atorvastatin ≥ 40 mg or rosuvastatin ≥ 20 mg daily) plus ezetimibe 10 mg daily.
 - c. Member has a current LDL-C level ≥ 100 mg/dL with contraindication or intolerance to statins (See Appendices B and C) and is taking ezetimibe 10mg daily.
 - d. Member has a current LDL-C level ≥ 100 mg/dL and contraindication to both statins and ezetimibe (See Appendix C).

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for members who have received Praluent through a pharmacy or medical benefit and who achieve or maintain an LDL-C reduction (e.g., LDL-C is now at goal, robust lowering of LDL-C).

Praluent SGM P2017

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. ® Registered trademark of CareFirst of Maryland, Inc.

IV. APPENDICES

APPENDIX A. Clinical ASCVD

- Acute coronary syndromes
- Myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization procedure (e.g., percutaneous coronary angioplasty [PTCA], coronary artery bypass graft [CABG] surgery)
- Stroke of presumed atherosclerotic origin
- Transient ischemic attack (TIA)
- Non-cardiac peripheral arterial disease of presumed atherosclerotic origin (e.g., carotid artery stenosis)
- Obstructive coronary artery disease (defined as fifty percent or greater stenosis on cardiac computed tomography angiogram or catheterization)

APPENDIX B. Statin-associated muscle symptoms (SAMS) and statin re-challenge

- Intolerable SAMS persisting at least two weeks, which subsided when the medication was discontinued, and reemerged with a statin re-challenge.
NOTE: Re-challenge must be with a different statin.
- Statin-associated elevation in CK level ≥ 10 times upper limit of normal (ULN)
NOTE: Statin re-challenge is NOT required for members who have experienced an elevation of CK level greater than or equal to 10 times ULN after receiving lipid-lowering therapy (LLT) with a statin.

APPENDIX C. Contraindications to statins and ezetimibe

- Contraindications to statins
 - Active liver disease, including unexplained persistent elevations in hepatic transaminase levels (e.g., alanine transaminase (ALT) level ≥ 3 times ULN)
 - Women who are pregnant or may become pregnant
 - Nursing mothers
- Contraindication to ezetimibe
 - Hypersensitivity reactions (e.g., anaphylaxis, angioedema, rash and urticaria)

APPENDIX D: Diagnosis of familial hypercholesterolemia (FH)

A diagnosis of FH is made when one of the following diagnostic criteria is met:

- Genetic confirmation
 - An LDL-receptor mutation, familial defective apo B-100, or a PCSK9 gain-of-function mutation
- Simon-Broome Diagnostic Criteria for FH
 - Total cholesterol > 290 mg/dL or LDL-C > 190 mg/dL in patients over 16 years of age or total cholesterol > 260 mg/dl or LDL-C > 155 mg/dl in patients less than 16 years of age and one of the following
 - Tendon xanthomas in the patient, first (parent, sibling or child) or second degree relative (grandparent, uncle or aunt)
 - Family history of myocardial infarction in a first degree relative before the age of 60 or in a second degree relative before the age of 50
 - Total cholesterol greater than 290 mg/dl in an adult first or second degree relative
 - Total cholesterol greater than 260 mg/dl in a child, brother, or sister aged younger than 16 years
- Dutch Lipid Clinic Network Criteria for FH
 - Total score > 5 points

V. REFERENCES

1. Praluent [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; October 2015.
2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129:S1-S45.
3. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the

role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2016;68:92-125.

4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387-97.
5. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 — full report. *J Clin Lipidol*. 2015;9:129–169.
6. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. *Eur Heart J*. 2013;34:3478–3490.
7. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *Eur Heart J*. 2014;35:2146-2157.
8. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;385:341-350.
9. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Arch Med Sci*. 2015;11:1-23.
10. Sabatine MC, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *New England Journal of Medicine*. 2017; Published online before print.
11. Lipitor [package insert]. New York, NY: Pfizer, Inc.; March 2015.
12. Crestor [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2015.
13. Zetia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; August 2013.
14. Hulten EA, Carbonaro S, Petrillo SP, et al. Prognostic value of cardiac computed tomography angiography. *Journal of the American College of Cardiology*. 2011;57(10):1237-1247.
15. Min JK, Labounty TM, Gomez MJ, et al. Incremental prognostic value of coronary computed tomographic angiography over coronary artery calcium score for risk prediction of major adverse cardiac events in asymptomatic diabetic individuals. *Atherosclerosis*. 2014;232(2):298-304.